Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
ImpediMed Limited has announced that the recent U.S. tariffs on imports are not expected to have a significant impact on its business or supply chain in the short to medium term. The company’s SOZO device is manufactured in the U.S. with many components sourced locally, and it maintains a sufficient inventory to mitigate potential supply chain disruptions. ImpediMed will continue to monitor the situation and update stakeholders if necessary.
More about Impedimed Limited
ImpediMed Limited, founded in Brisbane, Australia, is a medical technology company that specializes in bioimpedance spectroscopy (BIS) technology to enhance patient health. The company produces the SOZO Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for various indications, including lymphoedema and heart failure. ImpediMed operates in the US and European markets, focusing on cancer-related lymphoedema with a SaaS subscription-based business model.
YTD Price Performance: -50.0%
Average Trading Volume: 63,968
Technical Sentiment Signal: Strong Buy
Current Market Cap: $48.14M
See more insights into IPD stock on TipRanks’ Stock Analysis page.